Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

5 Charged in Alleged Scheme to Steal Drug Secrets

By Drug Discovery Trends Editor | January 21, 2016

Five people were indicted in federal court on charges they took part in an alleged scheme to steal biopharmaceutical trade secrets fromGlaxoSmithKline and sell them to competitors in China.

The indictment, which includes charges such as conspiracy to steal trade secrets and conspiracy to commit wire fraud and money laundering, said many of the products allegedly targeted were designed to treat cancer or other serious diseases.

The U.S. attorney’s office alleges that GlaxoSmithKline scientist Yu Xue emailed and downloaded confidential information and worked with other defendants to set up three corporations to sell the stolen intellectual property. They also allege that former company scientist Lucy Xi also emailed confidential information.

Prosecutors said Xue, 45—who they said “is regarded as one of the top protein biochemists in the world”—worked primarily to develop anti-cancer drugs using proteins to target receptor sites on cancer cells.

“These types of anti-cancer drugs … typically cost pharmaceutical corporations more than $1 billion and many years to develop before they can be turned into a commercially successful product,” prosecutors said in the indictment. Authorities alleged that Xue “stole more than a dozen specific products, even products she was not directly researching and developing.”

Attorney Peter Zeidenberg said Wednesday that Xue had pleaded not guilty and would contest the charges; he said the defense believes “that at the end of the day she’ll be exonerated.”

Attorneys for 42-year-old Tao Li, of Nanjing, China; 45-year-old Tian Xue, of North Carolina; and 38-year-old Lucy Xi, of California, declined comment. An attorney for 36-year-old Yan Mei, of Nanjing, China couldn’t be found Wednesday.

Lead image photo credit: Busted!

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50